Disclosures for "Toxicities and Outcome after CD19-directed Chimeric Antigen Receptor T-cell Therapy for Neurolymphomatosis"
-
Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Therapeutics. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Johnson. Dr. Dietrich has received publishing royalties from a publication relating to health care.
-
Philipp Karschnia has nothing to disclose.
-
Author has nothing to disclose
-
The institution of Wolfgang Wick has received research support from Roche. The institution of Wolfgang Wick has received research support from Pfizer. The institution of Wolfgang Wick has received research support from Apogenix.
-
The institution of Dr. Martinez-Lage has received research support from NIH.
-
Ganesh Shankar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Depuy. The institution of Ganesh Shankar has received research support from NuVasive.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Dr. Kaulen has nothing to disclose.